Karyopharm Therapeutics | KPTI - Ebitda





Ebitda Veränderung Datum
AbbVie USD 5.37B 1.85B 2025-12
Abbott USD 3.27B 178M 2025-12
Amgen USD 5.14B 775M 2025-12
AstraZeneca USD 5.67B 1.29B 2026-03
BioCryst Pharmaceuticals USD 51.7M 30.14M 2025-09
Bristol-Myers Squibb USD 2.88B 1.36B 2025-12
Eli Lilly USD 12.14B 4.26B 2025-12
GlaxoSmithKline GBP 2.77B 1.65B 2026-03
Incyte USD 367.97M 46.53M 2026-03
J&J USD 7.19B 2.32B 2025-12
Karyopharm Therapeutics USD -26.2M 1.83M 2024-09
MacroGenics USD 21.95M 55.39M 2025-09
Merck USD 6.3B 2.09B 2025-12
Nektar Therapeutics USD -31.81M 70K 2023-09
Novartis USD 5.3B 530M 2026-03
Novartis USD 5.84B 235M 2025-09
Pfizer USD 5.99B 5.23B 2026-03
Regeneron Pharmaceuticals USD 1.2B 718.4M 2025-12
Roche Holding CHF 12.68B 2.36B 2024-06
Takeda JPY 150.25B 297.88B 2026-03
Tectonic Therapeutic USD -21.18M 365K 2025-12
TG Therapeutics USD 51.69M 19M 2025-12
Ultragenyx Pharmaceutical USD -99.43M 57.35M 2025-12
Xencor USD -51.05M 55.28M 2025-12